Completed
PHASE2
INTERVENTIONAL
NCT00082082
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
Interventions
Name:
Thymalfasin (thymosin alpha-1)
Type:
DRUG
Description:
Name:
Trans arterial chemoembolization (TACE)
Type:
PROCEDURE
Description:
Trial Information
NCT ID
NCT00082082
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
SciClone Pharmaceuticals
Last Updated
December 15, 2025